Program
Phenytoin
Also written as “Phenytoin (Ascoli)”, “Dilantin Infatabs (Phenytoin)” and “Phenytoin: Study Drug”.
Its studies are mostly in Epilepsy · Seizures · Hepatitis C, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 30 open or running | phase 1since Apr 20, 2010 | Apr 20, 2010 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Feb 20, 2008 | Feb 20, 2008 | none ahead |
| Janssen Infectious Diseases BVBA | 10 open or running | phase 1since Jul 4, 2012 | Jul 4, 2012 | none ahead |
| Johnson & Johnson | 10 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Merck | 10 open or running | phase 1since Mar 25, 2025 | Mar 25, 2025 | none ahead |
| Novartis | 11 open or running | phase 1since Aug 18, 2026 | Aug 18, 2026 | none ahead |
| Pfizer | 10 open or running | phase 1since Jun 14, 2024 | Jun 14, 2024 | none ahead |
| Zydus Lifesciences | 10 open or running | phase 1since Jun 23, 2021 | Jun 23, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2005First study: phase 3 study in EpilepsyNew to Johnson & JohnsonJohnson & Johnson · NCT00210782 · 262 enrolled
- Feb 20, 2008GlaxoSmithKline's first study: phase 1 study in EpilepsyNew to GlaxoSmithKlineGlaxoSmithKline · NCT00627575 · 119 enrolled · United States
- Apr 20, 2010Viatris's first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT01122940, NCT01122953
- May 12, 2011Phase 1 study in SeizuresViatris · NCT01355068 · 26 enrolled · Singapore
- Jul 4, 2012Janssen Infectious Diseases BVBA's first study: phase 1 study in Hepatitis CNew to Janssen Infectious Diseases BVBAJanssen Infectious Diseases BVBA · NCT01635829 · 24 enrolled · Netherlands
- Jun 23, 2021Zydus Lifesciences's first study: phase 1 study in HealthyNew to Zydus LifesciencesZydus Lifesciences · NCT04981704 · 74 enrolled · United States
- Jun 14, 2024Pfizer's first study: phase 1 study in EpilepsyNew to PfizerPfizer · NCT06466473 · 35 enrolled · United States
- Mar 25, 2025Merck's first study: phase 1 study in HealthyNew to MerckMerck · NCT06903715 · 14 enrolled · United States
- Aug 18, 2026Novartis's first study: phase 1 study in Healthy ParticipantsNew to NovartisNovartis · NCT07783503 · 30 planned · United Kingdom
Ahead
- Nov 13, 2026Primary completion: phase 1 study in Healthy ParticipantsNovartis · NCT07783503
TargetBeta
“Sodium channel alpha subunit blocker; Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07783503Healthy Participants · United Kingdom | 1 | Recruiting | Novartis | Nov 13, 2026 | 30 |
| NCT06903715Healthy · United States | 1 | Completed | Merck | May 8, 2025 | 14 |
| NCT06466473Epilepsy · United States | 1 | Completed | Pfizer | Oct 4, 2024 | 35 |
| NCT04981704Healthy · United States | 1 | Completed | Zydus Lifesciences | Jun 30, 2021 | 74 |
| NCT01635829Hepatitis C · Netherlands | 1 | Completed | Janssen Infectious Diseases BVBA | Aug 2012 | 24 |
| NCT01355068Seizures · Singapore | 1 | Completed | Viatris | Jun 2011 | 26 |
| NCT01122953Healthy · Mexico | 1 | Completed | Viatris | Jun 2010 | 34 |
| NCT01122940Healthy · Mexico | 1 | Completed | Viatris | Aug 2010 | 32 |
| NCT00627575Epilepsy · United States | 1 | Completed | GlaxoSmithKline | Sep 12, 2008 | 119 |
| NCT00210782Epilepsy | 3 | Completed | Johnson & Johnson | 262 |
How it is read
Names in the registry
- “Phenytoin”, 5 entries
- “Phenytoin (Ascoli)”, 1 entry
- “Dilantin Infatabs (Phenytoin)”, 1 entry
- “Phenytoin: Study Drug”, 1 entry
- “phenytoin”, 1 entry
Conditions, from the studies’ own filings
- Epilepsy, 3 studies
- Seizures, 1 study
- Hepatitis C, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.